Geroncellbein , a specialized pharmaceutical manufacturing company, announced on the 27th that it has signed a memorandum of understanding (MOU) with the Korean Academy of Dental Implantology (KAID) to promote academic development and clinical education in the field of dental implants.
This agreement aims to innovate implant treatment and advance patient-centered medical technologies through research and development related to dental regenerative medicine and implants, sharing clinical data, and expanding regenerative medicine approaches in clinical settings.
Geroncellbein possesses regenerative medicine technology based on polydeoxyribonucleotide (PDRN), and plans to support PDRN-related practical seminars and lectures at academic conferences and training sessions hosted by the society in the future.
Additionally, Geroncellbein is conducting joint research with the Korean Academy of Dental Implantology utilizing its proprietary patented technology, "Prism Technology Nano PDRN." Research topics include regeneration of bone defects around implants, enhancement of osseointegration, and verification of the combined effects of bone grafting materials and PDRN.
Jeroncellbein CEO Kim Deok-gyu said, “Through this agreement, we will strengthen the industry-academia cooperation system with academic societies and seek technological advancements in the field of dental regenerative treatment.”
Kim Seong-min, President of the Korean Society of Dental Implantology, said, “I expect this to be an opportunity to expand the possibilities of regenerative medicine approaches in dental implant treatment,” and added, “I hope that the cooperation between the two institutions will contribute to improving the quality of patient treatment.”
- See more related articles
You must be logged in to post a comment.